De Novo device
Valeda Light Delivery System
Lumithera, Inc. · Light Based Device For Dry Age-Related Macular Degeneration (SDE, Class II) · First FDA decision Nov 4, 2024, newest Nov 4, 2024Macular degeneration and retinal disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
6
Naming "Valeda"
MAUDE reports
12
Brand "Valeda", since 2015
PubMed studies
19
Mentioning "Valeda"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Valeda Light Delivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Valeda Light Delivery SystemNew device typeDe Novo
DEN230083 · Decided Nov 4, 2024 · 326 days after receipt
Device type: Light Based Device For Dry Age-Related Macular Degeneration (SDE) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular DegenerationNational analysisReview closedCAG-00066R4Updated Sep 18, 2026
- Ocular Photodynamic Therapy with Verteporfin for Macular DegenerationNational analysisReview closedCAG-00066R3Updated Sep 15, 2026
- Ocular Photodynamic Therapy with Verteporfin for Macular DegenerationNational analysisReview closedCAG-00066R2Updated Sep 15, 2026
- Ocular Photodynamic Therapy with Verteporfin for Macular DegenerationNational analysisReview closedCAG-00066RUpdated Sep 15, 2026
- Ocular Photodynamic Therapy with Verteporfin for Macular DegenerationNational analysisReview closedCAG-00066NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Valeda", any status and sponsor, newest update first.
- Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)Pivotal-lookingCompleted
LumiThera, Inc.Not on our public-company list
NCT04065490 · 100 participants · Start Sep 23, 2019 · Primary completion Jan 24, 2023
Device: Valeda Light Delivery System; Valeda Light Delivery System Sham Mode · For: Dry Age-related Macular Degeneration
Sites: Beverly Hills, California; Palo Alto, California; Altamonte Springs, Florida · 10 sites in all
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Valeda", and for the whole product code for context.
This brand
12 reports: 5 malfunction, 7 injury, 0 death
Whole product code SDE
12 reports: 5 malfunction, 7 injury, 0 death
Newest reports for this brand
3016232028-2026-00008 · Received Oct 19, 2026
Device type: Light Based Device For Dry Age-Related Macular Degeneration (SDE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Retinal Degeneration
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Valeda"[tiab]. The summary above synthesizes these.
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
Boyer D, Hu A, Warrow D, et al. · Retina · 2024Randomized Controlled Trial
- LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration.
Burton B, Parodi MB, Jürgens I, et al. · Ophthalmol Ther · 2023
- Short-Term Results of Multiwavelength Photobiomodulation in Retinitis Pigmentosa.
Siqueira RC, Pinho TS, Brandão CC · Clin Ophthalmol · 2024
- Swept-Source OCT and OCT Angiography Biomarkers in Dry AMD Treated with Photobiomodulation: A Prospective Study.
Palata Rezende M, Faria FA, Polido J, et al. · Photobiomodul Photomed Laser Surg · 2026
- Drugs for age-related macular degeneration.
Med Lett Drugs Ther · 2025
- LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS).
Jaffe GJ, Boyer D, Hu A, et al. · Retina · 2026Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.
Markowitz SN, Devenyi RG, Munk MR, et al. · Retina · 2020Randomized Controlled Trial
- Multiwavelength photobiomodulation in atrophic age-related macular degeneration.
Beretta F, Zucchiatti I, Sacconi R, et al. · Eur J Ophthalmol · 2025
- Non-Invasive Treatment of Early Diabetic Macular Edema by Multiwavelength Photobiomodulation with the Valeda Light Delivery System.
Kaymak H, Munk MR, Tedford SE, et al. · Clin Ophthalmol · 2023
- Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment - Case Report.
Sachdev A · Ophthalmol Ther · 2024
- Multiwavelength Photobiomodulation Improves Multiple Aspects of Visual Function in Early-Stage Dry Age-Related Macular Degeneration.
Küçükerdönmez C, Tedford SE · Ophthalmol Ther · 2025
- Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020.
Samanta A, Aziz AA, Jhingan M, et al. · Asia Pac J Ophthalmol (Phila) · 2021Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.